{"filing":{"accession_number":"0001193125-26-424739","cik":"0001515673","ticker":"RARE","company_name":"Ultragenyx Pharmaceutical Inc.","form":"8-K","filing_date":"2026-10-19","report_date":"2026-10-19","primary_document":"rare-20261019.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526424739/rare-20261019.htm"},"events":[{"id":35989,"run_id":33178,"accession_number":"0001193125-26-424739","anchor_item_number":"8.01","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.92,"summary":"This disclosure reports settlement of patent litigation with Navinta LLC regarding DOJOLVI® (triheptanoin), a marketed pharmaceutical product. The settlement grants a generic competitor a non-exclusive, royalty-free license to market a generic version beginning January 1, 2033 (potentially July 1, 2033 with pediatric exclusivity). This is material because it resolves patent protection for a marketed drug and establishes a specific date when generic competition will be permitted, directly affecting the product's commercial exclusivity and revenue potential.","company_name":"Ultragenyx Pharmaceutical Inc.","ticker":"RARE","filing_date":"2026-10-19","form":"8-K","submitted_at":null,"items":[{"id":40251,"accession_number":"0001193125-26-424739","item_number":"8.01","item_title":null,"event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.92,"reasoning":"This disclosure reports settlement of patent litigation with Navinta LLC regarding DOJOLVI® (triheptanoin), a marketed pharmaceutical product. The settlement grants a generic competitor a non-exclusive, royalty-free license to market a generic version beginning January 1, 2033 (potentially July 1, 2033 with pediatric exclusivity). This is material because it resolves patent protection for a marketed drug and establishes a specific date when generic competition will be permitted, directly affecting the product's commercial exclusivity and revenue potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T13:01:45.198149+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40251,"accession_number":"0001193125-26-424739","item_number":"8.01","item_title":null,"event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.92,"reasoning":"This disclosure reports settlement of patent litigation with Navinta LLC regarding DOJOLVI® (triheptanoin), a marketed pharmaceutical product. The settlement grants a generic competitor a non-exclusive, royalty-free license to market a generic version beginning January 1, 2033 (potentially July 1, 2033 with pediatric exclusivity). This is material because it resolves patent protection for a marketed drug and establishes a specific date when generic competition will be permitted, directly affecting the product's commercial exclusivity and revenue potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T13:01:45.198149+00:00","company_name":"Ultragenyx Pharmaceutical Inc.","ticker":"RARE","filing_date":"2026-10-19"}]}